Accuracy of low-density lipoprotein cholesterol estimation at very low levels

被引:0
作者
Renato Quispe
Aditya Hendrani
Mohamed B. Elshazly
Erin D. Michos
John W. McEvoy
Michael J. Blaha
Maciej Banach
Krishnaji R. Kulkarni
Peter P. Toth
Josef Coresh
Roger S. Blumenthal
Steven R. Jones
Seth S. Martin
机构
[1] Johns Hopkins University School of Medicine,Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine
[2] Medstar Good Samaritan/Union Memorial Hospital,Department of Medicine
[3] Cleveland Clinic,Department of Cardiovascular Medicine
[4] Welch Center for Prevention,Department of Hypertension, Chair of Nephrology and Hypertension
[5] Epidemiology,undefined
[6] and Clinical Research,undefined
[7] Department of Epidemiology,undefined
[8] Johns Hopkins Bloomberg School of Public Health,undefined
[9] Medical University of Lodz,undefined
[10] Atherotech Diagnostics Laboratory,undefined
[11] Department of Preventive Cardiology,undefined
[12] CGH Medical Center,undefined
[13] University of Illinois College of Medicine,undefined
来源
BMC Medicine | / 15卷
关键词
Low-density lipoprotein cholesterol; Very low; Accuracy; Friedewald estimation; Novel method; Clinical decision making;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 297 条
[1]  
Cohen JC(2006)Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 1264-72
[2]  
Boerwinkle E(2012)Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2631-9
[3]  
Mosley TH(2004)Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937-52
[4]  
Hobbs HH(2011)Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials QJM 104 109-24
[5]  
Ference BA(2005)Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267-78
[6]  
Yoo W(2013)Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev. 1 CD004816-94
[7]  
Alesh I(2014)Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials J Am Coll Cardiol 64 485-67
[8]  
Mahajan N(2013)2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 151-818
[9]  
Mirowska KK(2011)ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 1769-88
[10]  
Mewada A(2014)National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary J Clin Lipidol 8 473-97